<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="9" ids="16796">Melatonin</z:chebi> (5-15 mg/kg) protects male animals against <z:hpo ids='HP_0002140'>ischemic stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>We explored the potential interactions and synergistic neuroprotection of <z:chebi fb="9" ids="16796">melatonin</z:chebi> and <z:chebi fb="0" ids="50114">estrogen</z:chebi> using a panel of <z:chebi fb="23" ids="18059">lipid</z:chebi> peroxidation and radical-scavenging assays, primary neuronal cultures subjected to oxygen-<z:chebi fb="105" ids="17234">glucose</z:chebi> deprivation (OGD), and <z:chebi fb="0" ids="16412">lipopolysaccharide</z:chebi> (LPS)-stimulated RAW 264.7 cells </plain></SENT>
<SENT sid="2" pm="."><plain>Neuroprotective efficacy of <z:chebi fb="9" ids="16796">melatonin</z:chebi> was also evaluated in both reproductively active and ovariectomized female rats subjected to transient focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Relative to <z:chebi fb="9" ids="16796">melatonin</z:chebi> or <z:chebi fb="1" ids="23965">estradiol</z:chebi> (E2) alone, a combination of the two agents exhibited robust, synergistic <z:chebi fb="11" ids="22586">antioxidant</z:chebi> and radical-scavenging actions (P&lt;0.05, respectively) </plain></SENT>
<SENT sid="4" pm="."><plain>Additionally, the two agents, when combined at large doses, showed synergistic inhibition in the production of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor alpha (TNF-Î±) and interleukin-6 (IL-6) in the LPS-stimulated RAW 264.7 cells (P&lt;0.05, respectively) </plain></SENT>
<SENT sid="5" pm="."><plain>Alternatively, co-treatment with <z:chebi fb="9" ids="16796">melatonin</z:chebi> and E2 independently, but not combined, showed a U-shaped dose-responsive (hormetic) cytoprotection for neuronal cultures subjected to OGD </plain></SENT>
<SENT sid="6" pm="."><plain>When combined at a dosage either positively or negatively skewed from each optimal dosage, however, co-treatment caused synergistic neuroprotection </plain></SENT>
<SENT sid="7" pm="."><plain>Relative to vehicle-injected controls, <z:chebi fb="9" ids="16796">melatonin</z:chebi> given intravenously at 1-5 mg/kg, but not 0.1 or 15 mg/kg, significantly reduced <z:e sem="disease" ids="C0751955" disease_type="Disease or Syndrome" abbrv="">brain infarction</z:e> and improved neurobehavioral outcomes (P&lt;0.05, respectively) in reproductively active female rats </plain></SENT>
<SENT sid="8" pm="."><plain>In ovariectomized <z:hpo ids='HP_0001297'>stroke</z:hpo> rats, <z:chebi fb="9" ids="16796">melatonin</z:chebi> was only effective at a large dosage (15-50 mg/kg) </plain></SENT>
<SENT sid="9" pm="."><plain>These results demonstrate complex interactions and synergistic <z:chebi fb="11" ids="22586">antioxidant</z:chebi>, radical-scavenging, and anti-inflammatory actions between <z:chebi fb="1" ids="23965">estradiol</z:chebi> and <z:chebi fb="9" ids="16796">melatonin</z:chebi>, and highlight the potential need to rectify the <z:chebi fb="9" ids="16796">melatonin</z:chebi>'s hormetic dose-response by the level of circulating <z:chebi fb="1" ids="23965">estradiol</z:chebi> in the treatment of female <z:hpo ids='HP_0001297'>stroke</z:hpo> patients </plain></SENT>
</text></document>